# AI在肥胖患者中应用标准体重肝素列线图而未进行调整，导致aPTT过高和出血风险增加

- **ID:** `medical/incorrect-use-of-iv-heparin-nomogram-in-obese-patient`
- **领域:** medical
- **类别:** protocol_error
- **错误码:** `HEPARIN-OBESITY-DOSING-ERROR`
- **验证级别:** ai_generated
- **修复率:** 86%

## 根因

标准肝素列线图使用实际体重给药，但在肥胖患者（BMI > 30）中，肝素的分布容积与体重不成线性比例，使用实际体重可能导致过量给药；许多列线图建议使用调整体重或固定最大剂量。

## 版本兼容性

| 版本 | 状态 | 引入 | 弃用 |
|------|------|------|------|
| CHEST Guidelines for Antithrombotic Therapy 2023 | active | — | — |
| ACCP Heparin Dosing Nomograms 2022 | active | — | — |

## 解决方案

1. ```
   Use an obesity-adjusted dosing nomogram that calculates initial bolus and infusion rate using adjusted body weight (ABW = IBW + 0.4 × (actual weight - IBW)) for patients with BMI > 30.
   ```
2. ```
   Implement a maximum initial infusion rate of 18 units/kg/hour based on actual body weight, with a hard cap of 2000 units/hour for patients >110 kg, as recommended by some institutional protocols.
   ```
3. ```
   Require a pharmacist review of the heparin order for any patient with BMI > 35 before administration, using a clinical decision support alert.
   ```

## 无效尝试

- **** — Ideal body weight can underdose heparin, leading to subtherapeutic aPTT and increased risk of thrombosis. (70% 失败率)
- **** — Heparin clearance is not linearly proportional to weight in obesity; doses >20,000 units/day can accumulate and cause bleeding. (80% 失败率)
- **** — This reactive approach delays correction and increases the risk of bleeding before the first aPTT is checked. (60% 失败率)